Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
An Accountable Payment Model a “Win-Win-Win” Solution to Value-Based Care
By
Wayne Kuznar
Economics & Value
,
Value-Based Care
October 2015, Vol 6, No 9
The Triple Aim of better patient care, lower spending by payers, and the maintenance of financially viable practices and hospitals is achievable with condition-based payment models in oncology, said Harold D. Miller, MS, President and Chief Executive Officer, Center for Healthcare Quality and Payment Reform, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
AstraZeneca Commentary on Oncology Value Tools
By
Diane Sullivan
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
October 2015, Vol 6, No 9
As patients, providers, payers, and policymakers continue to seek ways to assess the value of cancer therapies by balancing clinical benefits and treatment costs, a number of tools have been released to define the value of medicines.
Read Article
Patients with Cancer Eager to Discuss Costs of Care with Their Oncologists
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
September 2015, Vol 6, No 8
Gone are the days when patients with cancer were, for the most part, protected from healthcare costs by their medical insurance. According to a recent study sponsored by the National Comprehensive Cancer Network and conducted by Ronan J. Kelly, MD, MBA, MBBCh, Assistant Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues, with high deductibles, escalating copayments, and cost-sharing requirements becoming the status quo, patients with cancer are now, more than ever, feeling the effects of financial toxicity, particularly young patients who are especially susceptible to filing for medical bankruptcy (Kelly RJ, et al.
J Oncol Pract
. 2015;11:308-312).
Read Article
Assessing the Cost-Effectiveness of Necitumumab in Squamous-Cell Lung Cancer
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
August 2015, Vol 6, No 7
Chicago, IL—An economic analysis presented by Daniel Goldstein, MD, of Emory University, Atlanta, GA, at the 2015 American Society of Clinical Oncology meeting, was conducted to see at what price will necitumumab (which is currently being reviewed by the FDA for use in metastatic squamous-cell lung cancer) be cost-effective. According to this analysis, necitumumab will have to be priced at less than $1300 per cycle to be cost-effective based on the accepted willingness-to-pay threshold of $150,000.
Read Article
Site of Service Significantly Impacts Cost of Chemotherapy
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
August 2015, Vol 6, No 7
Chicago, IL—An analysis of chemotherapy infusion by Aetna shows that approximately 75% of their patients still receive chemotherapy in a community oncology setting, suggested Michael A. Kolodziej, MD, National Medical Director for Oncology Strategy, Aetna at the 2015 American Society of Clinical Oncology meeting.
Read Article
Dissecting the Cost of Targeted Therapies in Oncology
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
,
Targeted Therapy
August 2015, Vol 6, No 7
Chicago, IL—It is not a surprise that targeted therapies are the main drivers of spending on anticancer drugs in the United States. At the 2015 American Society of Clinical Oncology meeting, researchers presented data from several major cancer centers about the cost of targeted therapies.
Read Article
The Missing Elements in Our Value-Based Care Discussions
By
Kevin Cast
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
August 2015, Vol 6, No 7
Although we all admire and support the efforts put forth by many experts to help quantify the “real” value of cancer medications, they still miss the mark in 2 dramatic ways.
Read Article
Addressing the Value of New Cancer Treatment Options Using the ASCO Model
By
Philip E. Johnson, MS, RPh, FASHP
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
August 2015, Vol 6, No 7
How can cancer care decisions be based on value? Two champions are starting to add science to this controversial discussion, which will eventually help all stakeholders make more informed decisions.
Read Article
ASCO’s Net Health Benefit: A Palliative Care Regimen Scores Higher than Active Treatment
By
Pamela Pelizzari, MPH
;
Bruce S. Pyenson, FSA, MAAA
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
August 2015, Vol 6, No 7
Medicare’s Oncology Care Model (OCM) proposes a partial shift in financial risk from Medicare to oncologists. This incentivizes oncologists to use higher-value, lower-cost services. Information such as the recently released American Society of Clinical Oncology (ASCO) framework to assess new cancer treatment options will likely garner keen interest among providers participating in the OCM or similar programs, to the benefit of providers, payers, and patients.
Read Article
ASCO’s Value Framework Promoting Accountability and Transparency
By
Joseph Morse
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
,
ASCO’s Value Framework
August 2015, Vol 6, No 7
The American Society of Clinical Oncology (ASCO) value framework essentially calls for accountability and transparency, which are qualities that are beneficial to providing complete care for patients and to improving positive patient outcomes.
Read Article
Page 5 of 18
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma